Literature DB >> 25519266

Necrotising soft tissue infection in a UK metropolitan population.

G E Glass1, F Sheil, J C Ruston, P E M Butler.   

Abstract

INTRODUCTION: Necrotising soft tissue infection (NSTI) is a rare but life threatening diagnosis. Geographic, economic and social variances influence presentation and prognosis. As the current literature does not reflect a UK metropolitan population, we conducted a retrospective chart review to establish pertinent features relevant to our practice.
METHODS: Patients with histologically confirmed diagnoses of NSTI presenting to two London teaching hospitals between January 2007 and July 2013 were included in the study. Features of presentation, surgical and medical management, microbiological findings and outcome were evaluated.
RESULTS: Twenty-four patients with histologically confirmed NSTI were included. Two age clusters were identified, with means of 46 years (standard deviation [SD]: 10 years) and 80 years (SD: 6 years). Pain, erythema and sepsis were common findings. Hypertension, hypercholesterolaemia and type II diabetes mellitus were common co-morbidities. A third of younger patients had human immunodeficiency virus or hepatitis C, with a quarter dependent on drugs and/or alcohol. The mean Laboratory Risk Indicator for Necrotising Fasciitis (LRINEC) score was 5.8 (SD: 3.3). The lower extremities, groin and perineum were common sites of infection. Fourteen patients required inotropic support and seventeen required transfusions. The median number of surgical procedures was 5 (range: 1-17). Group A Streptococcus was the most frequently identified pathogen. Five patients died. Being elderly, female sex and failure to use clindamycin as a first-line antibiotic were associated with significantly higher mortality.
CONCLUSIONS: In contrast to other recent series, group A streptococcal monomicrobial NSTI remains the most common presentation in our population. Survival is anticipated in young patients, regardless of premorbid status. Elderly patients have a poor prognosis. The negative predictive value of the LRINEC score is questioned. Use of clindamycin as a first-line antibiotic is supported.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25519266      PMCID: PMC4473899          DOI: 10.1308/003588414X14055925058553

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  28 in total

1.  Clinical and microbiological spectrum of necrotizing fasciitis in surgical patients at a Philippine university medical centre.

Authors:  Vincent Bryan D G Salvador; Michael D San Juan; James A Salisi; Rafael J Consunji
Journal:  Asian J Surg       Date:  2010-01       Impact factor: 2.767

2.  Early diagnosis and treatment of necrotizing fasciitis can improve survival: an observational intensive care unit cohort study.

Authors:  Kelly Bucca; Ryan Spencer; Neil Orford; Claire Cattigan; Eugene Athan; Anthony McDonald
Journal:  ANZ J Surg       Date:  2012-09-19       Impact factor: 1.872

3.  Necrotizing fasciitis: is the bacterial spectrum changing?

Authors:  Serafim Tsitsilonis; Claudia Druschel; Florian Wichlas; Norbert P Haas; Philipp Schwabe; Hermann-Josef Bail; Klaus-Dieter Schaser
Journal:  Langenbecks Arch Surg       Date:  2012-07-26       Impact factor: 3.445

4.  Trends in 393 necrotizing acute soft tissue infection patients 2000-2008.

Authors:  Nicole P Bernal; Barbara A Latenser; Janelle M Born; Junlin Liao
Journal:  Burns       Date:  2011-10-24       Impact factor: 2.744

5.  Outcomes from treatment of necrotizing soft-tissue infections: results from the National Surgical Quality Improvement Program database.

Authors:  Megan K Mills; Iris Faraklas; Cherisse Davis; Gregory J Stoddard; Jeffrey Saffle
Journal:  Am J Surg       Date:  2010-12       Impact factor: 2.565

6.  Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: a multicenter study.

Authors:  Lillian S Kao; Debbie F Lew; Samer N Arab; S Rob Todd; Samir S Awad; Matthew M Carrick; Michael G Corneille; Kevin P Lally
Journal:  Am J Surg       Date:  2011-05-04       Impact factor: 2.565

7.  The epidemiology of necrotizing fasciitis including factors associated with death and amputation.

Authors:  M S Dworkin; M D Westercamp; L Park; A McIntyre
Journal:  Epidemiol Infect       Date:  2009-04-07       Impact factor: 2.451

8.  The effect of prolonged ED stay on outcome in patients with necrotizing fasciitis.

Authors:  Yu-Cheng Hong; Meng-Hua Chou; Estella H Liu; Cheng-Ting Hsiao; Jen-Tse Kuan; Ju-Chan Lin; I-Chuan Chen
Journal:  Am J Emerg Med       Date:  2009-05       Impact factor: 2.469

9.  Risk factors, microbiological findings and outcomes of necrotizing fasciitis in New Zealand: a retrospective chart review.

Authors:  Dilip Kumar Das; Michael G Baker; Kamalesh Venugopal
Journal:  BMC Infect Dis       Date:  2012-12-12       Impact factor: 3.090

10.  Histologically confirmed necrotizing fasciitis: risk factors, microbiology, and mortality in Hawaii.

Authors:  Nuntra Suwantarat; Dominic C Chow; Wega Koss; Dagmar Lin; Alan D Tice
Journal:  Int J Infect Dis       Date:  2012-07-02       Impact factor: 12.074

View more
  18 in total

1.  The burden of bone, native joint and soft tissue infections on orthopaedic emergency referrals in a city hospital.

Authors:  A Howell; S Parker; K Tsitskaris; M J Oddy
Journal:  Ann R Coll Surg Engl       Date:  2016-01       Impact factor: 1.891

Review 2.  [Necrotizing fasciitis - a clinical diagnosis].

Authors:  C Scheid; M Dudda; M Jäger
Journal:  Orthopade       Date:  2016-12       Impact factor: 1.087

Review 3.  Laboratory risk indicator for necrotising fasciitis (LRINEC) score for the assessment of early necrotising fasciitis: a systematic review of the literature.

Authors:  J Bechar; S Sepehripour; J Hardwicke; G Filobbos
Journal:  Ann R Coll Surg Engl       Date:  2017-05       Impact factor: 1.891

4.  Necrotising fasciitis caused by metastatic endometrial cancer: a rare cause of a life-threatening condition.

Authors:  S Hendrickson; N Bystrzonowski; C Kokkinos; P Butler
Journal:  Ann R Coll Surg Engl       Date:  2016-11-21       Impact factor: 1.891

5.  Frozen sections are unreliable for the diagnosis of necrotizing soft tissue infections.

Authors:  Isaac H Solomon; Rene Borscheid; Alvaro C Laga; Reza Askari; Scott R Granter
Journal:  Mod Pathol       Date:  2017-12-15       Impact factor: 7.842

6.  Necrotizing soft tissue infection: clinical characteristics, diagnosis, and management of 32 cases in Beijing.

Authors:  Zhen Cui; Shuai Lu; Ying Bai; Xu Sun; Peng Tian; Ying Liu; Lu Mao; Xieyuan Jiang
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

7.  What Demographic and Clinical Factors Are Associated with In-hospital Mortality in Patients with Necrotizing Fasciitis?

Authors:  Jaret Karnuta; Joseph Featherall; Joshua Lawrenz; Jaymeson Gordon; Joshua Golubovsky; Jonah Thomas; Deepak Ramanathan; Claus Simpfendorfer; Lukas M Nystrom; Maja Babic; Nathan W Mesko
Journal:  Clin Orthop Relat Res       Date:  2020-08       Impact factor: 4.755

8.  Improvement of a Clinical Score for Necrotizing Fasciitis: 'Pain Out of Proportion' and High CRP Levels Aid the Diagnosis.

Authors:  Thomas Borschitz; Svenja Schlicht; Ekkehard Siegel; Eric Hanke; Esther von Stebut
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

9.  Association between cytokine response, the LRINEC score and outcome in patients with necrotising soft tissue infection: a multicentre, prospective study.

Authors:  Marco Bo Hansen; Lars Simon Rasmussen; Mattias Svensson; Bhavya Chakrakodi; Trond Bruun; Martin Bruun Madsen; Anders Perner; Peter Garred; Ole Hyldegaard; Anna Norrby-Teglund
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

10.  The laboratory risk indicator for necrotizing fasciitis (LRINEC) scoring: the diagnostic and potential prognostic role.

Authors:  Ayman El-Menyar; Mohammad Asim; Insolvisagan N Mudali; Ahammed Mekkodathil; Rifat Latifi; Hassan Al-Thani
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2017-03-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.